drugset / Trial / NCT06470191
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Phase 2/3
Recruiting
216 enrolled
Shanghai Jiaolian Drug Research and Development Co., Ltd
Shanghai Pharmaceuticals Holding Co., Ltd · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
Timeline
- Start
- 2024-07-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | B007 | Monoclonal antibody | — | Subcutaneous |
| Comparator | Cyclosporine | Peptide | 3.5 mg/kg | Oral |